Cannabigerol, or CBG, is a cannabinoid that functions a lot like CBD, but it is far less abundant in hemp. CBG’s scarcity makes it harder to extract and thus more difficult (and more expensive) for consumers to find, but it’s becoming more well-known.
In simple words, CBGa is the mother compound from which all the other cannabinoids originate (THC, CBD, CBN, CBC, CBL).
Although a precursor compound, CBG is found only in smaller quantities (＜1%). Hence, several sources label them as rare and group them under minor cannabinoids. Nevertheless, its non-psychotropic nature and therapeutic effects have drawn attention and interest among the scientific community, cannabis companies, biotech companies, and investors alike. Market survey enthusiasts are avidly exploring the demand potential of rare cannabinoids and their impact on the health and wellness market.
CBGa is the first cannabinoid to be formed in the hemp or cannabis plant.
In the growing cannabis plants, most of the compounds develop as carboxylic acids such as THCa, CBDa, CBCa, THCVa and CBGa (the acidic form of CBG). That means, in the living plants, THC, CBD, CBG, or other decarboxylated neutrals are not present in large amounts.
Non-intoxicating, non-psychoactive cannabinoids like CBD and CBG are showing promising potential as a stand-alone or adjunct therapy in handling depression and anxiety.
The therapeutic potential of CBG in managing symptoms of Glaucoma, neurodegenerative diseases, inflammatory bowel diseases, and cancer are encouraging so far in animal model studies. But results from studies so far are still inconclusive and inadequate. Moreover, there is scope for further qualitative and quantitative research to be conducted.